| Trial ID: | L5178 |
| Source ID: | NCT03928379
|
| Associated Drug: |
Ly3305677
|
| Title: |
A Study of LY3305677 in Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3305677|DRUG: Placebo
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through 24 weeks | Secondary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3305677, PK: Cmax of LY3305677, Baseline through 48 hours postdose|PK: Area Under the Concentration-Time Curve (AUC) of LY3305677, PK: AUC of LY3305677, Baseline through 48 hours postdose|Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose, PD: Change from Baseline in Fasting Plasma Glucose, Baseline, through Week 16|PD: Change from Baseline in Fasting Plasma Insulin, PD: Change from Baseline in Fasting Plasma Insulin, Baseline, through Week 16
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SEQUENTIAL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2019-10-27
|
| Completion Date: |
2021-07-08
|
| Results First Posted: |
|
| Last Update Posted: |
2021-07-19
|
| Locations: |
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, 41460, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT03928379
|
